Accepted Manuscript Use of efavirenz or atazanavir/ritonavir is associated to better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort Maria Concetta Postorino , Mattia Prosperi , Eugenia Quiros-Roldan , Franco Maggiolo , Simona Di Giambenedetto , Annalisa Saracino , Silvia Costarelli , Silvia Lorenzotti , Laura Sighinolfi , Massimo Di Pietro , Carlo Torti PII:
S1198-743X(14)00088-3
DOI:
10.1016/j.cmi.2014.10.022
Reference:
CMI 87
To appear in:
Clinical Microbiology and Infection
Received Date: 2 July 2014 Revised Date:
8 October 2014
Accepted Date: 23 October 2014
Please cite this article as: Postorino MC, Prosperi M, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Saracino A, Costarelli S, Lorenzotti S, Sighinolfi L, Di Pietro M, Torti C, the MASTER Study Group, Use of efavirenz or atazanavir/ritonavir is associated to better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort, Clinical Microbiology and Infection (2014), doi: 10.1016/j.cmi.2014.10.022. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
1
Use of efavirenz or atazanavir/ritonavir is associated to better clinical outcomes of HAART
2
compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort
3 Authors:
5
Maria Concetta Postorino1, Mattia Prosperi2, Eugenia Quiros-Roldan3, Franco Maggiolo4, Simona
6
Di Giambenedetto5, Annalisa Saracino6, Silvia Costarelli7, Silvia Lorenzotti8, Laura Sighinolfi9,
7
Massimo Di Pietro10, Carlo Torti1,3 and the MASTER Study Group.
8
Affiliations:
SC
9
RI PT
4
1. Infectious Diseases Unit, “Magna Graecia” University Catanzaro 2. University of Manchester, UK
11
3. Infectious and Tropical Diseases Institute, University of Brescia
12
4. Ospedali Riuniti Bergamo
13
5. Catholic University of Sacred Heart Rome
14
6. Policlinico di Bari
15
7. Ospedale “S. Gerardo” Monza
16
8.
17
9. “S. Anna” Hospital Ferrara
18
10. “S. M. Annunziata” Hospital Florence
TE D
M AN U
10
EP
Istituti Ospitalieri Cremona
Corresponding author: Carlo Torti, Campus Universitario “Salvatore Venuta”, Viale Europa,
20
Catanzaro, Italy, 88100 Tel: +39 0961 3647162 Fax:+39 0961 364 7544 email:
[email protected]
21 22
AC C
19
Running title: Short and mid-term predictors of clinical outcomes during HAART
23 24
Key words: Non-nucleoside reverse transcriptase inhibitors, ritonavir boosted protease inhibitors,
25
first-line therapy, virological response, immunological response, AIDS events, deaths, composite
26
outcome.
1
ACCEPTED MANUSCRIPT
Abstract
28 29
Background
30
Randomized trials and observational cohorts reported higher rates of virological suppression after
31
highly active antiretroviral therapy (HAART) including efavirenz (EFV) compared with boosted
32
protease inhibitors (PIs). Correlations with immunological and clinical outcomes are unclear.
33
Methods
34
Patients of the Italian MASTER cohort who started HAART from 2000 to 2010 were selected. Out-
35
standing outcome (composite outcome for success-COS) was introduced. We evaluated predictors
36
of COS (no AIDS plus CD4+ count >500/mm3 plus HIV-RNA
